Full-Time

Director – Regulatory Affairs Strategy

Oncology

Confirmed live in the last 24 hours

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

10,001+ employees

Develops medicines for serious diseases

Biotechnology
Healthcare

Compensation Overview

$198k - $330kAnnually

Expert

Westchester County, NY, USA + 2 more

More locations: Berkeley Heights, NJ, USA | Tarrytown, NY, USA

This role requires you to work onsite 3 days per week in either Basking Ridge, NJ, Armonk, NY, or Tarrytown, NY.

Category
Risk & Compliance
Legal & Compliance

You match the following Regeneron Pharmaceuticals's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Excellent written and verbal communication skills
  • MD, Ph.D. or Pharm D. degree
  • Minimum of 10 years of pharmaceutical industry experience
  • At least 7 years of regulatory experience
Responsibilities
  • Provide leadership on global regulatory activities for assigned products
  • Focus on Clinical Regulatory filings
  • Support clinical study activities
  • Lead and/or supervise IND/CTA and BLA submissions activities
  • Provide interpretation of regulatory authorities’ feedback, policies and guidelines
  • Lead the development of regulatory strategic plans
  • Work with project teams to resolve complex project issues
  • Ensure quality and timeliness of IND/CTA and BLA submissions
  • Interact with other functions and partners in the preparation, review, and completion of documents for regulatory submissions
  • Plan, prioritize, supervise and/or conduct activities in collaboration with leads from other areas
  • Assure compliance with regulations and project team timelines
  • Provide interpersonal support and lead personnel
Desired Qualifications
  • Strong understanding of US FDA and international pharmaceutical guidance, regulations, drug development process, and industry standard practices
  • Experience interacting with CROs in the management of ex-US/ex-EU CTAs towards clinical trial activations
  • High attention to detail; ability to coordinate and prioritize assigned projects according to company goals
  • Strong interpersonal skills both written and verbally
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops medicines aimed at treating serious diseases such as cancer, eye diseases, and allergic conditions. The company uses its own technologies and extensive research to create new therapies, often collaborating with academic institutions and other pharmaceutical companies to enhance its efforts. This collaboration helps Regeneron stay updated with scientific advancements. Revenue comes from selling approved medicines and licensing technologies, often through partnerships that share development costs and profits. Regeneron works with healthcare providers and regulatory agencies to ensure its products are safe and effective, with the goal of improving patient outcomes.

Company Size

10,001+

Company Stage

IPO

Total Funding

$684M

Headquarters

Town of Greenburgh, New York

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing antibody therapy market offers expansion opportunities for Regeneron.
  • Investment in Truveta's genome project accelerates personalized medicine initiatives.
  • Acquisition of Oxular strengthens Regeneron's position in retinal disorder treatments.

What critics are saying

  • Class action lawsuit may lead to financial liabilities and reputational damage.
  • Truveta investment might not yield expected returns, posing financial risk.
  • Integration challenges with Oxular could affect operational efficiency.

What makes Regeneron Pharmaceuticals unique

  • Regeneron leverages proprietary technologies for innovative therapies in serious diseases.
  • Strategic collaborations enhance Regeneron's research and development capabilities.
  • Regeneron's focus on eye diseases and monoclonal antibodies sets it apart.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Paid Vacation

Equity Awards

Annual Bonuses

Flexible Work Hours

Company News

PharmiWeb
Jan 29th, 2025
Antibody Therapy Market To Surge, Expected To Reach Usd 824 Billion By 2033 At A 13.4% Of Cagr

Antibody Therapy MarketThe global antibody therapy market is on a strong growth trajectory, projected to expand at a CAGR of 13.4% from 2023 to 2033. With a valuation of USD 235 billion in 2023, the market is expected to surpass USD 824 billion by the end of the forecast period, driven by advancements in monoclonal antibody therapies and increasing demand for targeted treatments.The growing preference for protein-based, non-chemical treatments has fueled the adoption of monoclonal antibody therapy, particularly for cancer and cell-based diseases. Enhanced research and development efforts, supported by government funding, are further strengthening the effectiveness and accessibility of these treatments. Additionally, the expansion of cancer-specialized hospitals is boosting demand for antibody therapies.The market saw a significant boost during the COVID-19 pandemic, with the FDA approving advanced antibody therapies for treatment, leading to an accelerated CAGR of 18.2% between 2017 and 2022. As immunotherapy and chemotherapy resistance challenges continue, monoclonal antibodies have emerged as a promising alternative due to their high efficacy and reduced side effects.Request a Sample Report Now to get Premium Insights: https://www.futuremarketinsights.com/report-sample#5245502d47422d3134333632Key Takeaways:The antibody therapy market is set to grow from USD 235 billion in 2023 to USD 824 billion by 2033 at a CAGR of 13.4%.Rising cancer prevalence, regulatory approvals, and R&D collaborations are key growth drivers.Monoclonal antibodies offer a promising alternative to traditional chemotherapy, addressing tumor resistance and reducing side effects.Increased demand for targeted therapies and expanded healthcare infrastructure are expected to fuel long-term market growth.Key Growth DriversIncreasing Prevalence of Chronic Diseases The rising incidence of chronic diseases, particularly cancer and autoimmune disorders, is a significant driver for the antibody therapy market. As these conditions become more prevalent, the demand for effective treatment options, such as monoclonal antibodies, increases

PR Newswire
Jan 23rd, 2025
America'S Top 40 High School Scientists To Compete For $1.8 Million In Awards At Prestigious Regeneron Science Talent Search

The Regeneron Science Talent Search Celebrates and Rewards Today's Most Talented Young Minds Driving Innovation and Progress through Scientific ExplorationTARRYTOWN, N.Y. and WASHINGTON, Jan. 23, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in the 2025 Regeneron Science Talent Search (STS), the U.S.'s longest-running and most distinguished science, technology, engineering and math (STEM) competition for high school seniors

Rome Sentinel
Jan 13th, 2025
ATTENTION NASDAQ: REGN INVESTORS: Contact Berger Montague About a Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

ATTENTION NASDAQ: REGN INVESTORS: contact Berger Montague about a Regeneron pharmaceuticals, inc. class action lawsuit.

GeekWire
Jan 13th, 2025
Truveta secures $320M for genome project

Seattle-based health data company Truveta secured $320 million in funding to launch the Truveta Genome Project, aiming to create the largest and most diverse genomic dataset. The investment, from 17 health systems, Illumina, and Regeneron, elevates Truveta's valuation to over $1 billion. Regeneron will sequence exomes of 10 million volunteers. Truveta's total funding is nearly $500 million, with Microsoft as the exclusive cloud provider for the project.

Fierce Biotech
Jan 13th, 2025
JPM25: Regeneron, Illumina and more back Truveta for 10M genome sequencing project

To kick off the project, Regeneron made an upfront strategic investment of $119.5 million into Truveta, while Illumina chipped in $20 million as part of a series C financing.